[{"address1": "One Amgen Center Drive", "city": "Thousand Oaks", "state": "CA", "zip": "91320-1799", "country": "United States", "phone": "805 447 1000", "fax": "805 447 1010", "website": "https://www.amgen.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.", "fullTimeEmployees": 28000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert A. Bradway", "age": 61, "title": "Chairman, CEO & President", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 6428574, "exercisedValue": 0, "unexercisedValue": 50993104}, {"maxAge": 1, "name": "Mr. Peter H. Griffith", "age": 65, "title": "Executive VP & CFO", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 3007214, "exercisedValue": 0, "unexercisedValue": 1401880}, {"maxAge": 1, "name": "Dr. David M. Reese M.D.", "age": 61, "title": "Executive VP & CTO", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 3327225, "exercisedValue": 0, "unexercisedValue": 7193319}, {"maxAge": 1, "name": "Mr. Murdo  Gordon", "age": 57, "title": "Executive Vice President of Global Commercial Operations", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 3174030, "exercisedValue": 0, "unexercisedValue": 4835902}, {"maxAge": 1, "name": "Dr. James E. Bradner M.D.", "age": 52, "title": "Executive Vice President of Research & Development", "yearBorn": 1972, "fiscalYear": 2024, "totalPay": 4095677, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Esteban  Santos", "age": 56, "title": "Executive Vice President of Operations", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 3006074, "exercisedValue": 0, "unexercisedValue": 12988893}, {"maxAge": 1, "name": "Mr. Matthew C. Busch", "age": 49, "title": "Chief Accounting Officer & VP of Finance", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Scott  Skellenger", "title": "Senior VP & Chief Information Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Howard Y. Chang M.D., Ph.D.", "title": "Senior VP of Global Research & Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Justin G. Claeys", "title": "Vice President of Investor Relations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 8, "compensationRisk": 5, "shareHolderRightsRisk": 2, "overallRisk": 3, "governanceEpochDate": 1746057600, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-IRHome", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 275.84, "open": 269.99, "dayLow": 266.025, "dayHigh": 274.78, "regularMarketPreviousClose": 275.84, "regularMarketOpen": 269.99, "regularMarketDayLow": 266.025, "regularMarketDayHigh": 274.78, "dividendRate": 9.52, "dividendYield": 3.45, "exDividendDate": 1747353600, "payoutRatio": 0.8323, "fiveYearAvgDividendYield": 3.0, "beta": 0.497, "trailingPE": 24.882513, "forwardPE": 13.217707, "volume": 1848107, "regularMarketVolume": 1848107, "averageVolume": 3078108, "averageVolume10days": 2697540, "averageDailyVolume10Day": 2697540, "bid": 260.08, "ask": 284.55, "bidSize": 1, "askSize": 1, "marketCap": 146906644480, "fiftyTwoWeekLow": 253.3, "fiftyTwoWeekHigh": 346.85, "priceToSalesTrailing12Months": 4.3048306, "fiftyDayAverage": 299.2092, "twoHundredDayAverage": 302.85934, "trailingAnnualDividendRate": 9.13, "trailingAnnualDividendYield": 0.0330989, "currency": "USD", "tradeable": false, "enterpriseValue": 196891852800, "profitMargins": 0.17386, "floatShares": 536345722, "sharesOutstanding": 537705984, "sharesShort": 14543828, "sharesShortPriorMonth": 15062987, "sharesShortPreviousMonthDate": 1741910400, "dateShortInterest": 1744675200, "sharesPercentSharesOut": 0.0271, "heldPercentInsiders": 0.0021600001, "heldPercentInstitutions": 0.82025003, "shortRatio": 4.28, "shortPercentOfFloat": 0.0271, "impliedSharesOutstanding": 537705984, "bookValue": 11.544, "priceToBook": 23.66684, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": 5933000192, "trailingEps": 10.98, "forwardEps": 20.67, "lastSplitFactor": "2:1", "lastSplitDate": 943228800, "enterpriseToRevenue": 5.77, "enterpriseToEbitda": 12.52, "52WeekChange": -0.11832768, "SandP52WeekChange": 0.08001411, "lastDividendValue": 2.38, "lastDividendDate": 1739491200, "quoteType": "EQUITY", "currentPrice": 273.21, "targetHighPrice": 400.0, "targetLowPrice": 185.0, "targetMeanPrice": 315.34885, "targetMedianPrice": 317.5, "recommendationMean": 2.40625, "recommendationKey": "buy", "numberOfAnalystOpinions": 26, "totalCash": 8810000384, "totalCashPerShare": 16.384, "ebitda": 15726000128, "totalDebt": 57380999168, "quickRatio": 0.736, "currentRatio": 1.17, "totalRevenue": 34126000128, "debtToEquity": 924.456, "revenuePerShare": 63.49, "returnOnAssets": 0.07037, "returnOnEquity": 1.0567299, "grossProfits": 23569999872, "freeCashflow": 13090124800, "operatingCashflow": 12192000000, "revenueGrowth": 0.094, "grossMargins": 0.69068, "ebitdaMargins": 0.46082002, "operatingMargins": 0.28726998, "financialCurrency": "USD", "symbol": "AMGN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "marketState": "REGULAR", "regularMarketChangePercent": -0.95345306, "regularMarketPrice": 273.21, "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 3078108, "fiftyTwoWeekLowChange": 19.909988, "fiftyTwoWeekLowChangePercent": 0.0786024, "fiftyTwoWeekRange": "253.3 - 346.85", "fiftyTwoWeekHighChange": -73.640015, "fiftyTwoWeekHighChangePercent": -0.21231084, "fiftyTwoWeekChangePercent": -11.8327675, "dividendDate": 1749168000, "earningsTimestamp": 1746129667, "earningsTimestampStart": 1754305140, "earningsTimestampEnd": 1754654400, "earningsCallTimestampStart": 1746131400, "earningsCallTimestampEnd": 1746131400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 10.98, "epsForward": 20.67, "epsCurrentYear": 20.79282, "priceEpsCurrentYear": 13.139631, "fiftyDayAverageChange": -25.999207, "fiftyDayAverageChangePercent": -0.086893074, "twoHundredDayAverageChange": -29.649353, "twoHundredDayAverageChangePercent": -0.097898096, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.4 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 424704600000, "regularMarketChange": -2.630005, "regularMarketDayRange": "266.025 - 274.78", "shortName": "Amgen Inc.", "longName": "Amgen Inc.", "corporateActions": [{"header": "Dividend", "message": "AMGN announced a cash dividend of 2.38 with an ex-date of May. 16, 2025", "meta": {"eventType": "DIVIDEND", "dateEpochMs": 1747368000000, "amount": "2.38"}}], "regularMarketTime": 1746725721, "exchange": "NMS", "messageBoardId": "finmb_24816", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "displayName": "Amgen", "trailingPegRatio": 0.9263, "__fetch_time": "2025-05-08"}]